Anixa Biosciences, Inc. (FRA:CY71)
Germany · Delayed Price · Currency is EUR | Market Cap | 106.70M +27.0% |
| Revenue (ttm) | n/a |
| Net Income | -8.55M |
| EPS | -0.26 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 3.065 |
| Previous Close | 3.105 |
| Day's Range | 3.065 - 3.065 |
| 52-Week Range | 2.020 - 5.000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 9, 2026 |
About Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to addr... [Read more]
News
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, li...
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Breas...
Anixa Biosciences granted Australian patent for breast cancer vaccine
Anixa Biosciences (ANIX) announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa’s breast cancer vaccine technology. This patent, exclusively licensed from Clev...
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property coverage in markets with increasing breast cancer...
Anixa Biosciences, Moffitt Cancer advance ovarian cancer CAR-T trial
Anixa Biosciences (ANIX) announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T/CER-T th...
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg followin...
Anixa Biosciences assumed with a Buy at D. Boral Capital
D. Boral Capital analyst Patrick McCann assumed coverage of Anixa Biosciences (ANIX) with a Buy rating and $10 price target The firm says recent presentations highlighted final Phase 1 results…
Anixa Biosciences granted first Korean patent for breast cancer vaccine
Anixa Biosciences (ANIX) announced that the Korean Ministry of Intellectual Property has issued Patent Number 10-2960889 related to Anixa’s breast cancer vaccine technology. This composition-of-matter...
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate Expands global intellectual pr...
Anixa Biosciences reports results from two clinical-stage immunotherapy programs
Anixa Biosciences (ANIX) announced that its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy symposium this week. The pre...
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Ovarian cancer CAR-T therapy, l...
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial Breast cancer vaccine presentation to include final Phase 1 data sh...
Anixa Biosciences Quarterly report: Q2 2026
Anixa Biosciences has published its Q2 2026 quarterly earnings report on June 10, 2026.
Anixa Biosciences Slides: Corporate presentation
Anixa Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Anixa Biosciences: CIPO issues Notice of Allowance for patent
Anixa Biosciences (ANIX) announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering key aspects of Anixa’s ovarian cancer vaccine technology. The a...
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer SAN JOSE, Calif., June 1, 2026 /PRNewswire/ -- Anixa Biosciences...
Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer
Anixa Biosciences (ANIX) announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the company’s follicle-stimulating hormone rec...
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Multiple patients have survived substantially beyond expected median survival, including onepatient who survived 28 months and several patients who remain alive with continued follow-up Lira-cel clini...
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
SAN JOSE, Calif., May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announ...
Anixa Biosciences awarded patent for breast cancer vaccine in Mexico
Anixa Biosciences (ANIX) announced that the Mexican Institute of Industrial Property, or IMPI, has issued Patent Number 432748, covering key aspects of the Company’s breast cancer vaccine technology. ...
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagnoses and higher triple-negative breast cancer incidence rates New patent will provide IP protection o...
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX...
Anixa Biosciences Transcript: Water Tower Research Insights Conference
Lean operations and strategic partnerships enable advancement of CAR-T and breast cancer vaccine programs with minimal cash burn. Promising early clinical results, especially in ovarian cancer, and a differentiated off-the-shelf vaccine approach position the company for key data releases and valuation growth in the next 12–18 months.
Anixa Biosciences Slides: Corporate presentation
Anixa Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Breast cancer vaccine met primary endpoints and generated protocol-defined immuneresponses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive ...